Iptacopan · Fabhalta

Small molecule

Also known as LNP023

Approvedregulatory verdict

Evidence outlook

Approved: Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy, Complement-Mediated Renal Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Chronic Kidney Disease · Phase 3Age-Related Macular Degeneration · Phase 2Generalized Myasthenia Gravis · Phase 3

Also approved (5)
US
  • Complement 3 Glomerulopathy FABHALTA is indicated for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
Product first approved 2023Outside this platform's coverageFDA label
EU
  • Adult patients with complement 3 glomerulopathy (C3G)
  • Monotherapy in adult patients with paroxysmal nocturnal haemoglobinuria (PNH)
Product first approved 2024EMA
JP
  • Paroxysmal nocturnal haemoglobinuria (PNH), adults; Japanese brand name written Fabihalta in katakana; date from the Novartis Japan release of 2024-06-24
Product first approved 2024novartis.com
CN
  • Adult PNH patients who have not previously received complement inhibitor therapy (NMPA notice updated 2024-04-30)
Product first approved 2024NMPA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (15)
Chronic Kidney Disease
Generalized Myasthenia Gravis
IgA Nephropathy
NCT06994845 · Novartis Pharmaceuticals
2025-11-27 – 2030-06-30 · Primary Immunoglobulin A Nephropathy (IgAN)
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT06934967 · Novartis Pharmaceuticals
2025-10-28 – 2031-11-13 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
NCT04747613 · Novartis Pharmaceuticals
2021-07-27 – 2027-10-18 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT05630001 · Novartis Pharmaceuticals
2023-04-24 – 2024-10-17 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Other / comorbidity
NCT03955445 · Novartis Pharmaceuticals
2019-10-03 – 2036-05-30 · C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
What this study did
NCT05795140 · Novartis Pharmaceuticals
2024-05-08 – 2032-07-27 · Atypical Hemolytic Uremic Syndrome
What this study did
NCT05935215 · Novartis Pharmaceuticals
2024-02-28 – 2029-07-19 · Atypical Hemolytic Uremic Syndrome
What this study did
NCT05755386 · Novartis Pharmaceuticals
2023-10-02 – 2029-05-31 · IC-MPGN
What this study did
NCT04889430 · Novartis Pharmaceuticals
2022-01-17 – 2026-04-11 · Atypical Hemolytic Uremic Syndrome
What this study did
Phase 2 (11)
Age-Related Macular Degeneration
Chronic Kidney Disease
IgA Nephropathy
NCT06797518 · Novartis Pharmaceuticals
2025-02-21 – 2027-11-27 · Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT02534909 · Novartis Pharmaceuticals
2015-09-09 – 2022-05-24 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT03439839 · Novartis Pharmaceuticals
2018-04-09 – 2022-02-28 · Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
What this study did
NCT03896152 · Novartis Pharmaceuticals
2019-04-05 – 2022-02-09 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Other / comorbidity
NCT06388941 · Novartis Pharmaceuticals
2024-08-05 – 2026-12-30 · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
What this study did
NCT05086744 · Novartis Pharmaceuticals
2021-12-21 – 2024-05-17 · Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
What this study did
NCT04154787 · Novartis Pharmaceuticals
2019-11-23 – 2023-01-20 · Idiopathic Membranous Nephropathy
What this study did
NCT03832114 · Novartis Pharmaceuticals
2019-02-20 – 2021-04-23 · Glomerulonephritis
What this study did
Phase 1 (1)
Early phase / not applicable (2)
Other / comorbidity
NCT07347990 · First Affiliated Hospital of Zhejiang University
2026-08-25 – 2029-12-31 · Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)
What this study did
NCT06847607 · Bing Han
2025-03-01 – 2026-06-30 · AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Age-Related Macular Degeneration: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Iptacopan (Fabhalta): this drugPhase 2Small moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eylea)ApprovedProtein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Reliable signal
NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0)
NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42%
Aflibercept-Abzv (Enzeevu)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)ApprovedProtein / enzyme therapeuticVEGF-AReliable signal
NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97)
Aflibercept-Boav (Eydenzelt)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Avacincaptad Pegol (Izervay)ApprovedRNA AptamerComplement C5Reliable signal
NCT04435366: 12-month geographic-atrophy growth: 0.336 vs 0.392 mm/year for avacincaptad pegol vs sham; difference 0.056 mm/year (95% CI 0.016 to 0.096; p=0.0064). 24-month geographic-atrophy growth: 2.23 vs 2.59 mm²/year for monthly avacincaptad pegol vs sham; difference 0.362 mm²/year (95% CI 0.066 to 0.657; p=0.0165).
NCT02686658: Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence (Baseline and 12 months): Zimura 2 mg [Part 1 & Part 2 Combined] 0.292 millimeters (mm) (Standard Error 0.077) | Zimura 4 mg [Part 2] 0.321 millimeters (mm) (Standard Error 0.074) vs Sham [Part 1 & Part 2 Combined] 0.402 millimeters (mm) (Standard Error 0.075) | Sham [Part 2] 0.444 millimeters (mm) (Standard Error 0.072)
Brolucizumab-DbllApprovedAntibody fragmentVEGF-AWeak signalNo reviewed efficacy summary in this indication
FaricimabApprovedMultispecific antibodyAngiopoietin-2 / VEGF-APartial signal
NCT03823287: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 5.8 vs 5.1 letters, adjusted mean difference 0.7 (95% CI -1.1 to 2.5); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
NCT03823300: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 6.6 vs 6.6 letters, adjusted mean difference 0.0 (95% CI -1.7 to 1.8); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
Pegcetacoplan Ophthalmic (Syfovre)ApprovedPeptideComplement C3, Complement C3 / C3bReliable signal
NCT03525613: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.5579 mm^2 (Standard Error 0.0835) | Pegcetacoplan EOM 1.6512 mm^2 (Standard Error 0.08118) vs Sham Pooled 1.9692 mm^2 (Standard Error 0.08218)
NCT03525600: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 (Baseline (screening) and Month 12): Pegcetacoplan Monthly 1.7344 mm^2 (Standard Error 0.07924) | Pegcetacoplan EOM 1.7563 mm^2 (Standard Error 0.07446) vs Sham Pooled 1.964 mm^2 (Standard Error 0.09592) missed
Ranibizumab (Lucentis)ApprovedAntibody fragmentVEGF-APartial signal
NCT00056836: Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.
Ranibizumab-Eqrn (Cimerli)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Verteporfin (Visudyne)ApprovedSmall moleculeBenzoporphyrin-derivative photosensitizer for photodynamic therapyPartial signal
NCT00436553: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 (Baseline and Month 12): Verteporfin SF + Ranibizumab — Baseline: 53.7 Letters (Standard Deviation 13.52); Month 12: 59 Letters (Standard Deviation 17.47); Change from baseline: 5.3 Letters (Standard Deviation 15.66) | Verteporfin RF + Ranibizumab — Baseline: 54.6 Letters (Standard Deviation 12.78); Month 12: 59 Letters (Standard Deviation 18.03); Change from baseline: 4.4 Letters (Standard Deviation 15.47) vs Ranibizumab Monotherapy — Baseline: 54.8 Letters (Standard Deviation 13.55); Month 12: 63 Letters (Standard Deviation 18.88); Change from baseline: 8.1 Letters (Standard Deviation 15.09) missed
NCT00121407: VIO trial, 24-month primary endpoint: 47% of verteporfin-PDT patients vs 53% of placebo patients lost ≥15 letters (not significant); source states n=384 vs task record's 364, but sponsor/design/QLT-era details match this trial (2:1 randomization, occult CNV, no classic component). missed
Axitinib Intravitreal Implant (OTX-TKI)Phase 3Small moleculeVEGF receptors + PDGF receptorsPartial signal
NCT06223958: Superiority primary endpoint at week 36: 74.1% with AXPAXLI vs 55.8% with aflibercept 2 mg lost fewer than 15 ETDRS letters (2026-02-17).
BAT5906Phase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
CKD-701 (Lucenbies)Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT04857177: Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%).
HLX04-OPhase 3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ximluci)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RC28-EPhase 3Protein / enzyme therapeuticVEGF-A / FGF-2 (dual blockade)Partial signal
NCT04270669: Mean BCVA improvement from baseline at week 48: 6.1 ± 8.3 letters (0.5 mg), 9.9 ± 10.7 letters (1.0 mg), 7.6 ± 9.4 letters (2.0 mg)
Surabgene LomparvovecPhase 3Gene therapy / editingVEGF-AWeak signal
NCT04832724: Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0
Tabirafusp TedromerPhase 3Multispecific antibodyVEGF + IL-6Partial signal
NCT06556368: Primary endpoint: tabirafusp tedromer non-inferior to aflibercept on vision (p=0.0036); anatomical key secondary endpoint p<0.0001 (DAYBREAK, 2026-09-28).
Tarcocimab TedromerPhase 3Monoclonal antibodyVEGF-APartial signal
NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76)
NCT06556368: Primary endpoint, BCVA: met (p=0.0007) (Kodiak topline, 2026-09-28).
VonaprumentPhase 3Antibody fragmentComplement C1qPartial signal
NCT04656561: GA lesion growth vs sham at 12 months: 6.2% reduction monthly (p=0.526), 1.3% every-other-month (p=0.896), 3.7% pooled (p=0.673); primary endpoint not statistically significant. missed
MW02Phase 2/3Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary in this indication
BI 1584862Phase 2——not yet gradedNo reviewed efficacy summary in this indication
BI 771716Phase 2Antibody fragment—Weak signalFeatured results are safety only in this race
FWY003
Phase 2(overall)
UndisclosedComplement Factor B
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-6628Phase 1/2Antibody fragmentComplement C5not yet gradedNo reviewed efficacy summary in this indication
SAR402663Phase 1/2Gene therapy / editingVEGFnot yet gradedNo reviewed efficacy summary in this indication
SAR446597Phase 1/2Gene therapy / editingComplement C1s + Factor Bbnot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LazucirnonDiscontinuedSmall moleculeCCR3Partial signal
NCT04331730: Mean change in BCVA (ETDRS letters) from baseline to Week 36: AKST4290 800 mg + aflibercept +10.4 (SD 10.26, n=36), AKST4290 1600 mg + aflibercept +6.7 (SD 7.89, n=35), placebo + aflibercept +13.7 (SD 7.60, n=36); no between-group analysis posted (CT.gov posted results).

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fabhalta (Iptacopan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated VasculitisActive not recruiting
Est. primary completion 2026-12-30 · NCT06388941 · CT.gov ↗
What to watch
2027 (5)
January 2027 (1)
Phase 3C3GRecruiting
Est. primary completion 2027-01-29 · NCT04817618 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Generalized Myasthenia GravisActive not recruiting
Est. primary completion 2027-04-30 · NCT06517758 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaActive not recruiting
Est. primary completion 2027-10-18 · NCT04747613 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2IgA NephropathyRecruiting
Est. primary completion 2027-11-27 · NCT06797518 · CT.gov ↗
What to watch
December 2027 (1)
Early phase / not applicableThrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)Recruiting
Est. primary completion 2027-12-31 · NCT07347990 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
Phase 3Atypical Hemolytic Uremic SyndromeRecruiting
Est. primary completion 2028-07-21 · NCT05935215 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3IC-MPGNRecruiting
Est. primary completion 2028-10-27 · NCT05755386 · CT.gov ↗
What to watch
2030 (2)
June 2030 (1)
Phase 3IgA NephropathyRecruiting
Est. primary completion 2030-06-28 · NCT06994845 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2030-12-04 · NCT04557462 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2031-10-14 · NCT06934967 · CT.gov ↗
What to watch
2032 (1)
July 2032 (1)
Phase 3Atypical Hemolytic Uremic SyndromeRecruiting
Est. primary completion 2032-07-16 · NCT05795140 · CT.gov ↗
What to watch
2036 (1)
May 2036 (1)
Phase 3C3 Glomerulopathy, Immune-complex-membranoproliferative GlomerulonephritisRecruiting
Est. primary completion 2036-05-30 · NCT03955445 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 July 2026ApprovalFDA grants traditional approval to Fabhalta in primary IgAN
US, FDA · Source ↗
16 October 2025Topline resultAPPLAUSE-IgAN (NCT04578834) Phase 3 final analysis met its primary endpoint
Novartis · Source ↗
20 March 2025ApprovalFDA approves Fabhalta for C3G
US, FDA · Source ↗